GRAIL
Update in progressGRAL (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryDiagnostics & Research
GRAIL, Inc. is a commercial-stage healthcare company focused on multi-cancer early detection and related services in the United States and abroad. It offers Galleri, a blood-based cancer screening test for asymptomatic individuals over 50, and a diagnostic aid to speed cancer diagnosis. It also provides development services for clinical studies, pilot testing, and research, plus a precision oncology platform for prognostication, risk, MRD, and recurrence monitoring. Based in Menlo Park, CA, since 2015.
Company score
- Sentiment
- 0.42
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.54
- Governance
- 0.19
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.20
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.31
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!